ACUTE LYMPHOBLASTIC LEUKEMIA

This study tests a powerful chemotherapy regimen (Hyper-CVAD) combined with the targeted drug ponatinib in people with a specific type of acute lymphoblastic leukemia (ALL) that has a genetic change called the Philadelphia chromosome. The goal is to see if this combination can be…

This study gives venetoclax to 165 people with blood cancers like leukemia and lymphoma who already benefited from the drug in earlier studies. The main goal is to track side effects and see how safe the drug is over a longer period. Participants must have tolerated the drug well…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to lower the risk of graft-versus-host disease, a common complication. The goal is to see i…

This study tests whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a certain type of acute lymphoblastic leukemia (ALL) live longer and stay cancer-free longer. About 488 adults with newly diagnosed BCR-ABL-negative B-ALL are participat…

This early-phase study tests a new type of immune cell therapy (huCART19-IL18) for people with certain blood cancers that have come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to better find and attack cancer cells. The main goa…

This early-stage trial tests a new drug called ziftomenib (KO-539) in people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or control the cancer…

This study tests a new treatment called rapcabtagene autoleucel (YTB323) for adults with several types of blood cancer, including chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. The treatment uses a patien…

This early-stage study tests a new approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatment. Doctors take a patient's own T cells (a type of immune cell), add a gene that helps them recognize and attack leukemia…

This study tests whether siltuximab can lessen the severity of cytokine release syndrome (CRS) and nerve-related side effects (ICANS) in 30 people receiving CAR-T cell therapy for blood cancers like lymphoma and multiple myeloma. The goal is to help patients recover faster from t…

This study tests a drug called inotuzumab ozogamicin in 40 adults with B-cell acute lymphoblastic leukemia who have minimal residual disease (small amounts of cancer left after treatment). The drug attaches to a marker on cancer cells and delivers a toxin to kill them. The goal i…

This study tests whether adding special 'veto' cells to a stem cell transplant can help donor cells grow in the body without causing severe graft-versus-host disease (GVHD). It includes 16 people aged 12-75 with various blood cancers or bone marrow failure. The veto cells are tre…

This study tests whether adding two adult cancer drugs, bortezomib and vorinostat, to standard chemotherapy can better treat acute lymphoblastic leukemia (ALL) in infants under 1 year old. The goal is to see if the combination is safe and helps reduce leukemia cells. About 50 inf…

This study tests adding a targeted drug called inotuzumab ozogamicin (InO) to standard treatment for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this combination can make the cancer disappear faster an…

This study tests a new way to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a fast-growing blood cancer. It combines low-intensity chemotherapy with targeted drugs (ponatinib and blinatumomab) to kill cancer cells and help the immune system fight …

This study tests a vaccine called Triplex to see if it can prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be dangerous for people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA…

This study is for people with high-risk acute leukemia or myelodysplastic syndrome (MDS). It tests a new way to prepare the body for a donor stem cell transplant by combining targeted radiation (TMLI) with two chemotherapy drugs. The goal is to find the safest dose that can kill …

This study tests a new radiation technique called total marrow and lymphoid irradiation (TMLI) given before a stem cell transplant from a half-matched donor. The goal is to deliver higher radiation to cancer cells while protecting healthy organs, potentially reducing serious side…

This study is for people with a fast-growing blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It combines a strong chemotherapy regimen (Hyper-CVAD) with a targeted drug (dasatinib) and, for some patients, a donor stem cell transplant. …

This study compares two types of stem cell donors for children, teens, and young adults with high-risk leukemia or myelodysplastic syndrome (MDS). Participants receive a stem cell transplant from either a partially matched family donor or a fully matched unrelated donor. The goal…

This early-phase study tests whether giving healthy donor natural killer (NK) cells along with two drugs (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach/esophageal, or blood cancers. The NK cells are meant to attack cance…

This study tests a personalized approach for children aged 1-18 with newly diagnosed acute lymphoblastic leukemia or lymphoma. Using genetic information from each child's cancer, doctors add targeted drugs or immunotherapy to standard chemotherapy to improve cure rates and reduce…

This study looks at the best way to give a chemotherapy drug called pegaspargase to children and teens with acute lymphoblastic leukemia (ALL). About 2,000 participants will receive either one or two doses during treatment to see which approach works better and causes fewer side …

This study tested a treatment plan for adults aged 65 and older with a type of blood cancer called acute lymphoblastic leukemia (ALL). The approach combined an immunotherapy drug (blinatumomab) with standard chemotherapy or another targeted drug (dasatinib). The goal was to see i…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease. About 313 adults with various blood cancers…

This study tests a new treatment for people with a hard-to-treat type of leukemia. The treatment uses the patient's own immune cells (T cells) that are modified to better find and kill cancer cells. A safety switch is added to turn the cells off if severe side effects occur. The …

This study tests FDA-approved CAR-T cell therapy in 150 people with certain blood cancers (acute lymphoblastic leukemia or large B-cell lymphoma) that have not responded to standard treatments. Participants receive their own immune cells that have been reprogrammed to attack canc…

This study compares two different chemotherapy and radiation regimens given before a stem cell transplant for adults with acute lymphoblastic leukemia (ALL) in remission. The goal is to see if a stronger regimen can reduce the chance of the cancer returning without increasing the…

This study tests a targeted cancer drug (imatinib) with two different chemotherapy plans in children and teens newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if a milder chemo regimen works just as well as a strong…

This study tests a modified chemotherapy plan for children with Down syndrome who are newly diagnosed with acute lymphoblastic leukemia (ALL). The treatment uses lower doses of certain drugs to reduce side effects while still fighting the cancer. About 60 children across Asia are…

This early-stage trial tests a new drug called GNC-038, a quad-specific antibody designed to attack cancer cells in people with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia. The main goals are to check the drug's safety, find the right dose, and see…

This study tests a personalized treatment where a child's own immune cells are modified in a lab to recognize and attack cancer cells that have a protein called CD19. It is for children and young adults with certain types of leukemia or lymphoma that have come back or not respond…

This study was designed to test the safety and best dose of a drug called revumenib in children with certain types of leukemia after they had a stem cell transplant. The goal was to see if revumenib could help prevent the cancer from returning. However, the trial was withdrawn be…

This study tests a new form of chemotherapy called calaspargase pegol (SC-PEG) in 240 children and teens with acute lymphoblastic leukemia or lymphoblastic lymphoma. The goal is to see if giving it every 3 weeks is as safe and effective as the standard drug Oncaspar given every 2…

This study tests whether adding blinatumomab to standard targeted therapy (TKI) can better treat adults with a specific type of leukemia (Ph+ ALL). About 17 participants will receive the drug combination after initial treatment. The goal is to see if more patients achieve a deep …

This large phase 3 study is testing different combinations and doses of chemotherapy drugs in over 9,000 children and young adults newly diagnosed with standard-risk B-cell acute lymphoblastic leukemia or localized B-cell lymphoblastic lymphoma. The goal is to find which treatmen…

This study looks at whether training parents in specific skills can improve learning and school functioning for Latino children with acute leukemia or lymphoma. About 214 families will take part, with some parents receiving a high-intensity program and others getting standard sup…

This study tracks how financial distress (worry about money) changes for parents of children aged 1 to 14 being treated for acute lymphoblastic leukemia. Researchers will survey 100 parents over time to understand what factors, like income or hospital policies, affect these money…

This study collects white blood cells from people with leukemia or lymphoma whose cancer has not been cured by standard treatments. The cells are stored and may later be used to create a personalized therapy called CAR T-cells. The goal is to make it easier for patients to get th…

This study collects blood and bone marrow samples from 550 people with blood cancers like leukemia and lymphoma. Researchers will study the samples in the lab to learn more about how these cancers work and find new ways to treat them. Participants give samples during their regula…

This study is testing a new blood test called AlloHeme that looks at DNA to see if a patient's own cells are coming back after a bone marrow transplant. The goal is to find out if this test can predict a relapse of leukemia or myelodysplastic syndrome earlier than current methods…

This study tests whether a high-intensity digital health program—including video coaching and a special website—can help children aged 6 to 12 who were treated for leukemia or lymphoma improve their learning and school performance. Many children with these cancers are cured, but …

This study follows over 1,500 young adults who survived childhood cancers like leukemia, brain tumors, and Hodgkin lymphoma. Researchers measure physical frailty—a set of five fitness tests—over five years to see if it predicts future health problems. The goal is to identify surv…

This study looks at how the bacteria in the gut (microbiome) might be linked to symptoms like pain, sleep problems, and anxiety in children aged 5-18 with acute lymphoblastic leukemia. Researchers will collect stool samples and symptom reports before, during, and after chemothera…

This study follows 350 stem cell transplant survivors to see how their heart, lungs, and muscles work together over two years. Researchers measure exercise capacity and other health markers to learn why transplant survivors have a higher risk of heart disease. Participants includ…